Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Provide signed written informed consent~* Have a diagnosis of POAG or OHT in both eyes, or one eye with POAG and the other with OHT.~* Qualifying corrected visual acuity in each eye~* Qualifying central corneal thickness in each eye~* Qualifying Day 1 IOP measurement at 3 time-points in both eyes~* Qualifying Anterior chamber angle~Exclusion Criteria:~* History of ocular surgery specifically intended to lower IOP~* Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period~* Advanced glaucoma in either eye~* Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry~* Any ocular surgery or ocular laser treatment within 180 days prior to Screening and throughout the study in either eye~* Females who are pregnant, nursing, or planning a pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug Arm: DE-117 QD (Type: EXPERIMENTAL): DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
- Test Arm: DE-117 BID (Type: EXPERIMENTAL): DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)

Based on this trial design, predict the completion outcome and termination type (if applicable).